Picturing Health have developed a short video explaining how dolutegravir, using preliminary data from the ODYSSEY trial, has gained approval for use in children.

Data from the ongoing P1093 and ODYSSEY (PENTA20) studies have led to the successful approval of ViiV Healthcare’s submission to the U.S. FDA of the adult formulation for children weighing ≥20kg and dolutegravir dispersible tablets for children of 4 weeks of age and older.